New initiatives support the firm’s plans for multiple avenues of revenue.Read More
Tags :22nd Century Group
The company anticipates modified-risk designation of its low-nicotine cigarettes. Read More
The company now has the same lab testing equipment and capabilities as outside facilities.Read More
The company is keen to license its nicotine reduction technology to the industry. Read More
The company expects to benefit greatly from an FDA plan to mandate lower nicotine levels.Read More
22nd Century’s VP brings scientific, regulatory and public health experience to the table. Read More
The company sees tremendous opportunity for its tobacco and cannabis business in 2021. Read More
CannaMetrix technology will enable the company to reduce the time frame for bringing plant lines and intellectual property to market. Read More
The breakthrough is expected to yield disruptive plant lines and new licensing opportunities.Read More
The new Buffalo location will help accommodate anticipated growth. Read More
